Key clinical point: In patients with schizophrenia, sarcosine is associated with a significant positive treatment effect on overall clinical symptoms but not cognitive functions.

Major finding: Compared with placebo, sarcosine achieved a significant effect on relieving overall clinical symptoms (standardized mean difference [SMD], 0.51; P less than .01); however, it showed a positive but nonsignificant effect on overall cognitive functions (SMD, 0.27; P =.10).

Study details: Meta-analysis of seven trials including 326 participants.

Disclosures: This work was supported by grants from the An Nan Hospital, the China Medical University Hospital, the National Health Research Institutes, and the Ministry of Science and Technology. The authors declared no conflicts of interest.